Role of Lipid Rafts in Pathogen-Host Interaction - A Mini Review

Rakesh Kulkarni1,2*, Erik A. C. Wiemer3 and Wen Chang2*

1 Molecular and Cell Biology, Taiwan International Graduate Program, National Defense Medical Center, Academia Sinica and Graduate Institute of Life Science, Taipei, Taiwan, 2 Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, 3 Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Netherlands

Lipid rafts, also known as microdomains, are important components of cell membranes and are enriched in cholesterol, glycopospholipids and receptors. They are involved in various essential cellular processes, including endocytosis, exocytosis and cellular signaling. Receptors are concentrated at lipid rafts, through which cellular signaling can be transmitted. Pathogens exploit these signaling mechanisms to enter cells, proliferate and egress. However, lipid rafts also play an important role in initiating antimicrobial responses by sensing pathogens via clustered pathogen-sensing receptors and triggering downstream signaling events such as programmed cell death or cytokine production for pathogen clearance. In this review, we discuss how both host and pathogens use lipid rafts and associated proteins in an arms race to survive. Special attention is given to the involvement of the major vault protein, the main constituent of a ribonucleoprotein complex, which is enriched in lipid rafts upon infection with vaccinia virus.

Keywords: lipid rafts, vaccinia virus, major vault protein, pathogen-host interactions, cell entry

INTRODUCTION

The fluid mosaic model of biological membranes was proposed by Singer and Nicolson in 1972, whereby membranes are composed of uniform lipid bilayers in which select proteins randomly float (1). Later studies have contradicted this hypothesis, revealing instead the presence of detergent-resistant and detergent-soluble fractions in cell membranes (2). This latter heterogeneity in cell membranes was identified to be due to the presence of lipid rafts or microdomains (3–5). Lipid rafts are small, dynamic, heterogeneous microdomains (10-200 nm) that are enriched in cholesterol and glycosphospholipids (6–9). High concentrations of sphingolipids and dense packing of protein with cholesterol in lipid rafts promotes cell membrane stability (10). Lipid rafts also contain a diverse group of cellular receptors (11–15) which play important roles in various cellular processes such as endocytosis, exocytosis, receptor trafficking and cell signaling (4). However, these same lipid rafts are also exploited by many pathogens to achieve cell entry and cell exit e.g. via budding (8, 16).

Abbreviations: ACE2, Angiotensin converting enzyme 2; CLEC5A, C-type lectin 5A; DC-SIGN, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin; GKN3, Gastrokinase 3; PLVAP, Plasmalemma vesicle associated protein; PMA- Phorbol 12-myristate 13-acetate; IGF1R- Insulin like growth factor 1 receptor; Tim-1, T-cell immunoglobulin and mucin domain-1; CAR-Coxsakievirus and adenovirus receptor; SCARB2 - Scavenger receptor B2; PSGL-1 - P-selectin glycoprotein ligand-1; SLAM - Signaling lymphocytic activation molecule; Anx2 - Heparan sulfate and annexin II.
Advancements in cell imaging approaches have allowed lipid rafts to be visualized in cells, with cholera toxin staining frequently used for confocal microscopy-based observations (17). Lipid rafts are relatively resistant to extraction by non-ionic detergents such as 1% Triton X-100 (4, 18, 19), but biochemical enrichment by detergent extraction followed by flotation centrifugation has enabled more detailed analyses of lipid rafts. Many lipid raft-specific markers have been identified, including flotillin and caveolin (12, 15). Important tools to study the impact of lipid rafts in various cell signaling pathways are methyl-β-cyclodextrin (MβCD), filipin and nystatin. These compounds are used to extract cholesterol from the plasma membrane and through preferentially targeting cholesterol in lipid rafts, depletes the raft structures (20, 21). Lipid rafts are also found in multiple cell types in brain such as neurons, astrocytes and microglia; several neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis and lysosomal storage disease were found to be associated with altered composition of lipid rafts (22–26). Overall, lipid rafts modulate multiple aspects of cellular functions that are important for cell survival, immune signaling as well as pathogen recognition and pathogen egress (Figure 1A), as described below.

**FIGURE 1** | Biological roles of lipid rafts in pathogen-host interactions: (A) Lipid rafts are involved in several cellular functions, such as pathogen recognition, cell signaling, and pathogen egress which decides the outcome of pathogen-host interaction. (B) Lipid rafts in pathogen sensing and cytokine release: Lipid rafts play an important role in pathogen sensing by recruiting pathogen sensing receptors such as toll like receptors when cells are stimulated with bacterial cell wall components LPS or LTA and C-type lectin receptors when stimulated with fungal cell wall components such as β-glucans which eventually leads to cytokine secretion.
LIPID RAFT INVOLVEMENT IN PATHOGEN RECOGNITION RECEPTOR SIGNALING AND CYTOKINE SECRETION

Lipid rafts play important roles in modulating host innate and adaptive immune responses against pathogens. Apart from harboring proteins important for phagocytosis of pathogens (27–29), lipid rafts accumulate pathogen recognition receptors - including c-type lectin receptors (CLRs) and Toll-like receptors (TLRs) - to detect pathogens and initiate downstream signaling cascades for cytokine release and complement system activation for pathogen clearance (30–32) (Figure 1B). TLR4 was found to be enriched in lipid raft fractions from cells stimulated with the specific ligand lipopolysaccharide (LPS), but not from non-stimulated cells, and depletion of lipid rafts by nystatin and filipin resulted in failure to produce the downstream cytokine TNF-α, suggesting that lipid rafts are important in TLR4 activation (33). Another TLR, Toll-like receptor 2 (TLR2) that recognizes cell wall components of lipoteichoic acid (LTA) in Gram-positive bacteria, is enriched in lipid rafts and transported to Golgi network upon cell treatment with LTA (34–36). Depletion of lipid rafts by MβCD or nystatin inhibited this enrichment of TLR2 and its transport to Golgi, implying a role for lipid rafts in TLR2 activation and trafficking (34–36). Similarly, host C-type lectins that sense carbohydrate-rich domains on fungi and activate downstream signaling events were also observed to be enriched in lipid rafts (37). Dectin-1 that is primarily expressed on dendritic cells, macrophages and neutrophils plays an important role in anti-fungal immunity (38). Upon sensing fungal zymosan or β-glucan, host dectin-1 was found to translocate with its downstream signaling molecules spleen tyrosine kinase (SYK) and phospholipase C gamma 2 (PLCγ2) to lipid rafts. Depletion of lipid rafts by MβCD treatment resulted in loss of SYK phosphorylation in dendritic cells, supporting a role for lipid rafts in dectin-1 signaling (39). During Streptococcus pneumoniae infection, splenic marginal zone (MZ) macrophage lipid rafts accelerate pathogen uptake and degradation (40), as well as mediate DC-SIGN- or SIGN-R1-induced classical complement pathway activation against S. pneumoniae, thereby facilitating rapid clearance of this pathogen.

Cytokines are soluble factors released by cells in response to infection and inflammation and they are key modulators of the immune system. Cytokine receptors are recruited to lipid rafts to mediate cytokine signaling. For example, tumor necrosis factor-α receptor 1 (TNFRI) and interferon alpha and beta receptor subunit 1 (IFNAR1) are enriched in lipid rafts, and depletion of lipid rafts reduced cytokine release (41, 42). Furthermore, release of cytokines from vesicles requires N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) mediated fusion with the plasma membrane. SNARE proteins, including syntaxin4 and synaptosomal associated protein-23, are enriched in lipid rafts of LPS-stimulated macrophages, facilitating release of the cytokine TNF-α (43). Other reports also showed that SNARE and Rab proteins are associated with lipid rafts (44, 45).

It is interesting that, although cytokine release is dependent on lipid rafts, the integrity of lipid rafts is also reciprocally affected by cytokine signaling. For example, interferon-induced viperin interacts with farnesyl diphosphate synthase (FPPS) to inhibit cholesterol synthesis and lipid raft formation (46), in addition to its role in catalyzing cytidine triphosphate (CTP) to 3′-deoxy-3′,4′-didehydro-CTP (ddhCTP) (46, 47).

ROLE OF LIPID RAFTS IN APOPTOSIS AND REDOX SIGNALING

Reactive oxygen species (ROS) produced in phagosomes eliminate pathogens through oxidative damage by innate immune cells such as neutrophils (48), representing an important element of inflammation and antimicrobial host defense. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) is a key source of ROS in host cells. NOX is a multimer that requires all components for assembly and enzymatic activity in lipid rafts to produce ROS (49). Depletion of lipid rafts limits ROS production due to failure to recruit cytosolic components of the NOX complex (i.e., P47phox, P67phox P40phox and RAC) to the plasma membrane, which already harbors the gp91phox and P22phox components upon priming with interleukin 8 (II-8) (50–52). Other adaptor molecules, such as protein kinase C involved in phosphorylating the NOX subunit P47phox, are also recruited to lipid rafts for ROS production. In another study, Mycobacterium tuberculosis 19-KDa lipoprotein, which is a TLR1/2 agonist, was shown to trigger translocation of TLR2 and protein kinase Cζ to lipid rafts and to induce ROS production (52). Disruption of lipid rafts in macrophages resulted in reduced M. tuberculosis lipoprotein-induced ROS production and recruitment of TLR2 and protein kinase Cζ, demonstrating that lipid rafts are critical to ROS production.

Low doses of ROS under steady-state conditions contribute to cell survival, whereas high doses of ROS induced by infection help clear pathogens by activating cell death pathways such as apoptosis and necroptosis. In the TNF (tumor necrosis factor)-induced necroptosis pathway, activation of mixed lineage kinase domain-like protein (MLKL) lead to oligomerization of receptor-interacting protein3 (RIPK3) which is translocated to lipid rafts in the plasma membrane where it enhances sodium influx to induce cell rupture (53). Lipid rafts also regulate other cell death pathways such as autophagy. Lipid rafts are found in mitochondria associated membranes that connect ER with mitochondria and are required for the correct assembly of vesicles and formation of autophagosomes (54–56).

CELLULAR ENTRY OR EGRESS OF PATHOGENS VIA LIPID RAFTS

Host-pathogen interactions determine the outcome of infections. Lipid rafts are a key component of host-pathogen interactions on cell surfaces, given their roles in initiating cell signaling, harboring receptors and mediating cell trafficking (57–59). Experimental drugs that interrupt lipid raft formation have
demonstrated that lipid rafts are important for cell entry of multiple viruses (Table 1). HIV-1 viral protein gp120 fuses with CD4+ T-cells through the lipid raft-associated receptors CD4, CCR5 and CXCR4 (60–62). Vaccinia mature virus (MV) clusters on lipid rafts where it interacts with the type II glycoprotein CD98 and integrin β1 to trigger endocytosis for cell entry (66, 67, 124). Both depletion of lipid rafts and knockdown of CD98 have been shown to reduce MV endocytosis, supporting the importance of lipid rafts in vaccinia virus entry into cells (66, 67). Hemagglutinin (HA) glycoprotein of influenza virus is important for virus-cell attachment and membrane fusion, which occurs more efficiently at lipid rafts of plasma membrane, suggesting that influenza virus employs lipid rafts for cell entry (69–71). Simian virus 40 (SV40), upon infection in cells, translocated to caveolae enriched membranes and specific disruption of caveolae with phosphatidylserine PMA or nystatin blocked SV40 entry (71). Human herpes virus-6 (HHV-6) enters cells through binding to cellular receptor CD46, which was enriched in lipid (74–77). As expected, depletion of cholesterol inhibited HHV-6 entry into cells (74–77). Similarly, polyomavirus and type c foot-and-mouth disease virus (FMDV) entry into the cells was also inhibited upon treatment with MβCD and was reversed upon addition of cholesterol suggesting role of lipid rafts in their entry (78, 79, 87). Flavivirus family members Japanese encephalitis virus (JEV), dengue virus serotype-2 (DEN-2) and West Nile virus (WNV) infection to cells was inhibited upon treatment with MβCD and cholesterol chelator filipin III. Surprisingly addition of cholesterol did not rescue cell susceptibility to JEV and DEN-2, unlike other viruses (81, 87). Several coronavirus family members such as mouse hepatitis virus (MHV), infectious bronchitis virus (IBV), human coronavirus 229E (HcoV-229E), severe acute respiratory syndrome virus (SARS-CoV), were shown to enter cells through lipid rafts (89, 91, 93, 96). A recent report also showed that pseudotyped virus containing SARS-CoV-2 spike protein enters cells through lipid rafts (99). African swine fever virus (ASFV) entry into pig macrophages is also dependent on lipid rafts as depletion of lipid rafts with cyclodextrins and nystatin blocked ASFV entry into pig macrophages (103, 104). Apart from viruses, bacterial pathogens also target lipid rafts during infection. For example, the enteric Gram-negative bacteria Shigella flexneri and Salmonella enterica enter cells by binding to lipid raft-associated receptors CD44 and CD55, respectively (125, 126). Depletion of lipid rafts impedes bacteria from binding to and entering host cells (127).

However, there are also studies indicating an opposing role for a lipid raft-associated protein, caveolin, during endocytic entry of the bacteria Staphylococcus aureus (128). Engagement of S. aureus by host integrin α5β1 via fibronectin was shown to trigger bacterial relocalization to lipid rafts. Surprisingly, caveolin deficiency, but not flotillin deficiency, enhanced S. aureus uptake. Recruitment of membrane lipids to the bacterial attachment site was not affected in Cav1−/− cells, suggesting that caveolin blocks S. aureus in a post-attachment step (128). Caveolin has also been proven essential in host defenses against the pathogens Pseudomonas aeruginosa and Salmonella enterica sv. Typhimurium (129, 130). Caveolin-knockout mice are susceptible to both bacteria, exhibiting increased bacterial burdens in several organs relative to non-infected controls (129, 130). It is interesting that caveolin-knockout mice display a severe inflammatory phenotype, with elevated levels of

### Table 1 | Lipid raft mediated viral entry and receptors involved.

| Virus                          | Receptors                        | Chemical and pharmaceutical drugs targeting lipid rafts                                      | References |
|-------------------------------|----------------------------------|------------------------------------------------------------------------------------------------|------------|
| Human immunodeficiency virus  | CD4, CCR5, CXCR4                 | MβCD, Cytochalasin, Nystatin, 25-Hydroxycholesterol, Atorvastatin                            | (60–65)    |
| Vaccinia virus                 | CD98, Integrin β1                | MβCD                                                                                          | (66–68)    |
| Influenza virus                | Sialic acid                      | MβCD, Cyclodextrin, Fluvasatatin                                                            | (69–72)    |
| Smoan virus 40                 | Ganglioside GM1                  | PAA, Nystatin, Filipin III                                                                      | (71, 73)   |
| Human herpes virus-6           | CD46                             | MβCD                                                                                          | (74–77)    |
| Polio virus                    | CD155                            | MβCD                                                                                          | (78)       |
| Foot-and-mouth disease virus   | Integrin αβ6                     | MβCD, Filipin III                                                                              | (79, 80)   |
| Japanese encephalitis virus    | PLVAP, GKN3                      | MβCD, Filipin III                                                                              | (81, 82)   |
| Dengue virus                   | DC-SIGN, Mannose receptor, CLEC5A| MβCD, Filipin III, Cycloextrins, Propofol,2,6-diisopropylphenol                              | (81, 83–86) |
| West Nile virus                | TLR3                             | MβCD                                                                                          | (87, 88)   |
| Mouse hepatitis virus          | CD66a                            | MβCD, Filipin III                                                                              | (89, 90)   |
| Infectious bronchitis virus    | Sialic acid                      | MβCD, Mevastatin                                                                               | (91, 92)   |
| Human coronavirus 229E         | CD13                             | MβCD, Chloroquine                                                                              | (93–94)   |
| SARS-CoV                       | ACE2                             | MβCD, Cholesterol 25-Hydroxylyase                                                              | (96–98)   |
| SARS-CoV-2                     | ACE2                             | MβCD, Fluvoxamine, 25-Hydroxycholesterol, Fluvasatatin                                        | (98–102)   |
| African swine fever virus      | CD163                            | Cycloextrins, Nystatin                                                                         | (103, 104) |
| Zika virus                     | DC-SIGN, AXL, Tyro3, Tim-1       | 25-Hydroxycholesterol, Chloroquine                                                            | (83, 105, 106) |
| Hepatitis C virus              | CD81, DC-SIGN, CD209L            | Fluvasatatin                                                                                   | (107, 108) |
| Respiratory Syncytial virus    | CX3CR1, IGF1R                    | Lovastatin, Cycloextrins                                                                        | (83, 109–112) |
| Ebola virus                    | Tim-1                            | Lovastatin, cycloextrins                                                                        | (113, 114) |
| Herpes simplex virus           | Heparan sulfate                  | Cycloextrins                                                                                   | (83, 115)   |
| Coxackievirus                  | CAR                              | Fluoxetine                                                                                     | (116)      |
| Enterovirus 71                 | SCARB2, Arx2, PSGL-1, sialylated glycan | Fluoxetine, Halothane, Simvastatin                                                       | (116–119) |
| Measles virus                  | CD46, SLAM                       | Halothane, Simvastatin                                                                         | (120, 121) |
| Murine Cytomegalovirus         | Heparan sulfate                  |                                                                                                 | (122, 123) |
inflammatory cytokines, chemokines in serum, and free radicals, implying complex biological functions of lipid raft-associated proteins in pathogen and host interactions (131). Pathogen interactions with lipid rafts are not solely restricted to the cell surface, since many intracellular pathogens could escape degradation by preventing phagosome fusion with lysosomes upon being internalized into cells (132). For example, *Leishmania donovani* utilizes lipophosphoglycans to disrupt dynein in lipid rafts and thereby avoids lysosomal degradation (132).

As for pathogen entry into cells, pathogen assembly and egress is crucial for its spread to other cells, tissues and hosts. Pathogens can manipulate the egress route by inducing programmed cell death (e.g., apoptosis) and cell rupture, by forming actin-mediated protrusions, or by inducing bud formation, with this latter potentially involving lipid rafts. Endosomal sorting complexes required for transport (ESCRT) are essential for membrane scission, as well as being involved in viral budding. Many enveloped viruses such as HIV, Murine Leukemia Virus (MLV) and vaccinia virus employ ESCRT-dependent budding or egress mechanisms (133–136). Knockdown of ESCRT complex members such as charged multivesicular body protein -2A (CHMP-2A) and CHMP-4B blocked the release of HIV and MLV (133, 136).

Proteomic analyses have revealed the presence of ESCRT complex proteins in isolated lipid raft fractions, implying a role in viral budding (137, 138). Cholesterol synthesis inhibitor lovastatin treatment reduced the dengue virus (DENV) production by blocking virion assembly and intracellular trafficking showing that lipid rafts are important not only for DENV entry but also for their release from cells (139).

**PHARMACEUTICAL DRUGS TARGETING LIPID RAFTS TO BLOCK PATHOGEN ENTRY AND INFECTION**

As described above, many pathogen attachment receptors are concentrated in the lipid rafts, hence targeting lipid rafts could be a good strategy to overcome infection (140, 141). Disruption of lipid rafts by chemical compounds such as MβCD, filipin, 25-hydroxycholesterol and cyclodextrins has already shown to block the entry of many pathogens into cells (63, 81, 83, 100, 105, 142, 143). Furthermore, several pharmaceutical drugs used in treatment of other disorders were found to interact with lipid rafts resulting in blocking the entry of pathogens into the cells. Some of the well-known drugs targeting lipid rafts are statins (144, 145), anesthetics (146), and psychotropic drugs (147–150). Several statins such as lovastatin, mevastatin, fluvastatin, simvastatin, atorvastatin and nystatin used for the treatment of cardiovascular disease were reported to block virus entry into cells (64, 65, 72, 101, 107, 109, 110, 113, 122). Similarly, anesthetic drugs such as propofol, halothane and barbiturates were found to block virus entry due to their interaction with lipid rafts (84, 120). Antidepressants act by displacing G protein responsible for increasing cAMP (Goα) from lipid rafts, and drugs such as fluvoxamine, and fluoxetine are known to block the entry of viruses (102, 116–118, 147, 149). Taken together, repurposing these existing drugs against newly emerging pathogenic virus may provide a good strategy since they have a proven safety record and can be deployed in a short time to treat viral infections. The list of potential pharmaceutical drugs targeting lipid rafts to block entry and propagation of viruses are included in Table 1.

**MAJOR VAULT PROTEIN (MVP) MODULATES IMMUNE SIGNALING AND PATHOGEN ENTRY**

MVP is a 100-kDa protein that constitutes the major component of vault complex in cells (151, 152). The vault particle is a huge (400 Å x 670 Å) cage-like structure of 12.9 Mda, consisting of MVP, vault poly (ADP-ribose) polymerase (VPARP/PARP4) and telomerase associated protein (TEP1) proteins and multiple copies of small untranslated vault RNAs (vRNAs) (153). MVP is widely expressed in many normal tissues and overexpressed in many multi-drug-resistant cancer cells (153–155). MVP and vault particles may act as scaffolds for proteins involved in signal transduction, such as the Janus kinase/signal transducer and activator of transcription proteins (JAK/STAT) (156), Phosphoinositide-3-kinase/protein kinase B (PI3K/AKT) (125) and ERK (157) signaling pathways. MVP has also been implicated in suppression of metabolic diseases, such as obesity and atherosclerosis, through IKK-NF-κB signaling-mediated inflammation (158). MVP negatively regulates osteoclast differentiation by inhibiting the calcineurin-NFATc1 signaling pathway (159). Moreover, it interacts with Src in an epidermal growth factor (EGFR)-dependent manner and downregulates Src tyrosine kinase activity in stomach tissue, with this latter being necessary for activation of extracellular signal-regulated kinase (ERK) signaling (160).

Interestingly, MVP and vault particles also play a role in pathogen, host interactions. For instance, vRNA induced by Epstein-Barr viral infections played a role in anti-viral host defense (161, 162). MVP was found to be enriched in lipid rafts following infection of human lung epithelial cells with *Pseudomonas aeruginosa* (163). Binding of *P. aeruginosa* LPS outer-core oligosaccharide to cystic fibrosis transmembrane conductance (CFTR) recruited MVP to lipid rafts and activate NF-κB signaling, IL-8 secretion and apoptosis induction. In MVP knockout (MVP−/−) mice bacteria uptake in lungs was reduced to 45% when compared with the wild-type mice. Further analyses concluded that MVP is critical for formation of stable membrane microdomains after *P. aeruginosa* infection. MVP translocation to lipid rafts was also induced by microbial metabolites such as N-(3-oxo-dodecanoyl) homoserine lactones (C12) released by proteobacteria and *Pseudomonas aeruginosa* (164) to modulate p38 pathway to reduce apoptotic cell death (164). In macrophages, MVP interacted with the scavenger receptor (SR-A/MSR1) in membrane rafts and modulated SR-A-caveolin-p38/JNK-mediated TNF-α production and apoptosis (165). MVP knockout (KO) mice grow normally showing that it
is not required during mouse embryogenesis (166) and yet these KO mice are more susceptible to infection with several pathogens, such as Influenza A virus and Pseudomonas aeruginosa, suggesting that MVP plays an important role in immune responses against viral and bacterial pathogens (163, 167). In our previous study to identify cellular proteins enriched in lipid rafts upon vaccinia virus infection we identified integrin β1 and CD98 proteins that play important roles in virus entry (66, 67). Interestingly, these proteomic data (66) (Figure 2A) also revealed MVP to be enriched ~5-fold in lipid rafts upon vaccinia virus infection (Figure 2B) (66). Increase of MVP in lipid rafts is transient and MVP is not involved in integrin β1 or CD98 interactions and whether it participates in other signaling events during vaccinia mature virus entry remains to be investigated. The role of MVP in several immune signaling pathways, as summarized in (Figure 2C), showed that it may exert important functions in host-pathogen interactions, warranting further detailed experimental study.
CONCLUSION AND FUTURE PERSPECTIVES

Lipid rafts on the plasma membrane are used as a portal for entry by many pathogens, including viruses and bacteria. Reorganization of cell surface lipid rafts during pathogen and virus entry could induce clustering of membrane receptors and/or intracellular molecules at the proximal inner membrane to facilitate entry, as well as to trigger signaling cascades. Thus, formation of such raft-associated protein complexes may reflect how pathogens and viruses engage with particular cellular receptors required for cell entry and invasion, how cells sense stress and mount immediate early anti-viral and anti-bacterial responses, and may even explain how viral proteins hijack lipid rafts to modify or antagonize cellular signaling and allow their propagation. Our understanding of the dynamic processes and rafts to modify or antagonize cellular signaling and allow their propagation. Reports in the literature highlight important, if not key roles for MVP recruited to lipid rafts upon pathogen exposure. Therefore, further detailed investigations are warranted to reveal the full functional potential of MVP in dealing with diverse pathogens in different cell types. A better and more precise delineation of the cellular function(s) of MVP, as well as the other components of the vault complex, will reveal interesting biology and possibly therapeutic opportunities.

AUTHOR CONTRIBUTIONS

RK, WC, and EW wrote and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

WC was supported by a grant from the Academia Sinica and Ministry of Science and Technology (110-2320-B-001-015-MY3).

REFERENCES

1. Singer SJ, Nicolson GL. The Fluid Mosaic Model of the Structure of Cell Membranes. Science (1972) 175(4023):720–31. doi: 10.1126/science.175.4023.720
2. Steck TL, Yu J. Selective Solubilization of Proteins From Red Blood Cell Membranes by Protein Perturbants. J Supramol Struct (1973) 1(3):220–32. doi: 10.1002/jss.400010307
3. Karnovsky MJ, Kleinfeld AM, Hoover RL, Klausner RD. The Concept of Lipid Domains in Membranes. J Cell Biol (1982) 94(1):1–6. doi: 10.1083/jcb.94.1.1
4. Simons K, Ikonen E. Functional Rafts in Cell Membranes. Nature (1997) 387 (6633):569–72. doi: 10.1038/42408
5. Lingwood D, Kaiser HJ, Levental I, Simons K. Lipid Rafts as Functional Heterogeneity in Cell Membranes. Biochem Soc Trans (2009) 37(Pt 5):955–60. doi: 10.1042/BST037955
6. Pike LJ. Rafts Defined: A Report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res (2006) 47(7):1597–8. doi: 10.1194/jlr.E600002-JLR200
7. Levental I, Veatch S. The Continuing Mystery of Lipid Rafts. J Mol Biol (2016) 428(24 Pt A):4749–64. doi: 10.1016/j.jmb.2016.08.022
8. Sezgin E, Levental I, Mayor S, Eggeling C. The Mystery of Membrane Organization: Composition, Regulation and Roles of Lipid Rafts. Nat Rev Mol Cell Biol (2017) 18(6):361–74. doi: 10.1038/nrm.2017.16
9. Levental I, Levental KR, Heberle FA. Lipid Rafts: Controversies Resolved, Mysteries Remain. Trends Cell Biol (2020) 30(5):341–53. doi: 10.1016/j.tcb.2020.01.009
10. Sezgin E, Kaiser HJ, Baumgart T, Schwille P, Simons K, Levental I. Elucidating Membrane Structure and Protein Behavior Using Giant Plasma Membrane Vesicles. Nat Protoc (2012) 7(6):1042–51. doi: 10.1038/nprot.2012.059
11. Otto GP, Nichols BJ. The Roles of Pholitlin Microdomains—Endocytosis and Beyond. J Cell Sci (2011) 124(23):3933–40. doi: 10.1242/jcs.092015
12. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. Pholitlin and Epidermal Surface Antigen Define a New Family of Caveolae-Associated Integral Membrane Proteins. J Biol Chem (1997) 272(21):17379–802. doi: 10.1074/jbc.272.21.173793
13. Stuermer CA, Lang DM, Kirsch F, Wiechers M, Deininger SO, Plattner H. Glycosylphosphatidyl Inositol-Anchor ed Proteins and Fyn Kinase Assembly in Noncaveolar Plasma Membrane Microdomains Defined by Regge-1 and -2. Mol Biol Cell (2001) 12(10):3031–45. doi: 10.1091/mbc.12.10.3031
14. Mora R, Bonilha VL, Marmorstein A, Scherer PE, Brown D, Lisanti MP, et al. Caveolin-2 Localizes to the Golgi Complex But Redistributes to Plasma Membrane, Caveolae, and Rafts When Co-Expressed With Caveolin-1. J Biol Chem (1999) 274(36):25708–17. doi: 10.1074/jbc.274.36.25708
15. Wilson BS, Steinberg SL, Liederkin K, Pfeffer JR, Surviladze Z, Zhang J, et al. Markers for Detergent-Resistant Lipid Rafts Occupy Distinct and Dynamic Domains in Native Membranes. Mol Biol Cell (2004) 15(6):2580–92. doi: 10.1091/mbc.e03-08-0574
16. Head BP, Patel HH, Insel PA. Interaction of Membrane/Lipid Rafts With the Cytoskeleton: Impact on Signaling and Function: Membrane/Lipid Rafts, Mediators of Cytoskeletal Arrangement and Cell Signaling. Biochim Biophys Acta (2014) 1838(2):532–45. doi: 10.1016/j.bbamem.2013.07.018
17. Kenworthy AK, Petranova N, Eddin M. High-Resolution FRET Microscopy of Cholera Toxin B-Subunit and GPI-Anchored Proteins in Cell Plasma Membranes. Mol Biol Cell (2000) 11(5):1645–55. doi: 10.1091/mbc.11.5.1645
18. Brown DA, Rose JK. Sorting of Gp-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains During Transport to the Apical Cell-Surface. Cell (1992) 68(3):533–44. doi: 10.1016/0092-8674(92)90189-J
19. Aureli M, Grassi S, Sonnino S, Prinetti A. Isolation and Analysis of Detergent-Resistant Membrane Fractions. Methods Mol Biol (1376) 2016:107–131. doi: 10.1007/978-1-4939-3170-5_10
20. Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of Cyclodextrins for Manipulating Cellular Cholesterol Content. J Lipid Res (1997) 38(11):2264–72. doi: 10.1016/S0022-2275(03)78940-3
21. Castanho MA, Coutinho A, Prieto MJ. Absorption and Fluorescence Spectra of Polyene Antibiotics in the Presence of Cholesterol. J Biol Chem (1992) 267(1):204–9. doi: 10.1016/S0021-9258(18)48400-3
22. Valsecchi M, Mauri L, Casellato R, Priono S, Loboerto N, Prinetti A, et al. Ceramide and Sphingomyelin Species of Fibroblasts and Neurons in Culture. J Lipid Res (2007) 48(2):417–24. doi: 10.1194/jlr.M600344-JLR200
23. Sonnino S, Aureli M, Grassi S, Mauri L, Priono S, Prinetti A. Lipid Rafts in Neurodegeneration and Neuroprotection. Mol Neurobiol (2014) 50(1):130–48. doi: 10.1007/s12035-013-0614-4
24. Chiricozzi E, Biase ED, Maggioni M, Lunghi G, Fazzari M, Pome DY, et al. GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal
65. Selvam MP, Blay RA, Geyer S, Buck SM, Pollock L, Mayner RE, et al. Inhibition of HIV-1 Replication in H9 Cells by Nystatin-A Compared With Other Antiviral Agents. AIDS Res Hum Retroviruses (1993) 9(5):475–81. doi: 10.1089/aid.1993.9.475

66. Schroeder N, Chung CS, Chen CH, Liao CL, Chang W. The Lipid Raft-Associated Protein CD98 Is Required for Vaccinia Virus Endocytosis. J Virol (2012) 86(9):4868–82. doi: 10.1128/JVI.06610-11

67. Izmailyan R, Haoo JC, Chung CS, Chen CH, Hsu PW, Liao CL, et al. Integrin Beta1 Mediates Vaccinia Virus Entry Through Activation of PI3K/Akt Signaling. J Virol (2012) 86(12):6677–87. doi: 10.1128/JVI.06680-11

68. Chung CS, Huang CY, Chang W. Vaccinia Virus Penetration Requires Cholesterol and Results in Specific Viral Envelope Proteins Associated With Lipid Rafts. J Virol (2005) 79(3):1623–34. doi: 10.1128/JVI.79.3.1623-1634.2005

69. Takeda M, Leser GP, Russell CJ, Lamb RA. In Envelope Components Enriched in Lipid Rafts: Evidence for Virion-Associated Lipid Rafts. J Virol (2003) 77:11823–34. doi: 10.1128/JVI.77.11.11823-11825

70. Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J. Protective Effect of Fluvastatin on Influenza Virus Infection. Med Mol Rep (2014) 9(6):2221–6. doi: 10.3802/mm.2014.2076

71. Luo Y, Motamedei N, Magaldi TG, Gee GV, Atwood JW, DiMaio D. Interaction Between Simian Virus 40 Major Capsid Protein VP1 and Cell Surface Ganglioside GM1 Triggers Vacuole Formation. mBio (2016) 7(2):e00297. doi: 10.1128/mBio.00297-16

72. Huang H, Li Y, Sadoaka T, Tang H, Yamamoto T, Yamanishi K, et al. Host Lipid Rafts Play a Major Role in Binding and Endocytosis of Influenza A Virus. Viruses (2018) 10(1):650. doi: 10.3390/v100101650

73. Anderson HA, Chen Y, Norkin LC. Bound Simian Virus 40 Translocates to Envelope Proteins Associated With Lipid Rafts. J Virol (2005) 79(3):1623–34. doi: 10.1128/JVI.79.3.1623-1634.2005

74. Huang H, Yuan Q, Wei Y, Gao Y, Mao L, et al. The Important Role of Lipid Raft-Mediated Attachment in the Infection of Cultured Cells by Drugs That Selectively Disrupt Caveolae. Mol Biol Cell (1996) 7(11):1825–34. doi: 10.1091/mbc.7.11.1825

75. Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J. Protective Effect of Fluvastatin on Influenza Virus Infection. Med Mol Rep (2014) 9(6):2221–6. doi: 10.3802/mm.2014.2076

76. Anderson HA, Chen Y, Norkin LC. Bound Simian Virus 40 Translocates to Caveolin-Enriched Membrane Domains, and Its Entry Is Blocked By Drugs That Selectively Disrupt Caveolae. Mol Biol Cell (1996) 7(11):1825–34. doi: 10.1091/mbc.7.11.1825

77. Li X, Zhu W, Fan M, Huang F, et al. Dependence of SARS-CoV-2 Entry Into Vero E6 Cells. Biochem Biophys Res Commun (2020) 526(1):34–9. doi: 10.1016/j.bbrc.2020.02.023

78. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-Converting Enzyme 2 Is a Functional Receptor for the SARS-CoV-2 Virus. Nature (2020) 426(6965):450–4. doi: 10.1038/nature21245

79. Wang S, Li W, Hui T, Tiwari SK, Zhang Q, Croker BA, et al. Cholesterol 25-Hydroxylase Inhibits SARS-CoV-2 and Other Coronaviruses by Depleting Membrane Cholesterol. EMBO J (2020) 39(21):e106057. doi: 10.15252/embj.2020106057

80. Li X, Zhu W, Fan M, Zhang J, Peng Y, Huang F, et al. Dependence of SARS-CoV-2 Infection on Cholesterol-Rich Lipid Raft and Endocytic Acidification. Comput Struct Biotechnol J (2021) 19:1933–43. doi: 10.1016/j.csbj.2021.04.001

81. Lu S, Deng YQ, Zhou C, Li J, Li L, Chen Q, et al. 25-Hydroxycholesterol Is a Potent SARS-CoV-2 Inhibitor. Cell Res (2020) 30(11):1043–5. doi: 10.1038/s41422-020-00389-1

82. Zapatero-Belinchón FJ, Moeller R, Lasswitz L, van Ham M, Becker M, Gruhl DJ, et al. Expression of Porcine CD163 on Monocytes/Macrophages Correlates With Permissiveness to African Swine Fever Virus Infection. Arch Virol (2003) 148(12):2307–23. doi: 10.1007/s00705-003-0188-4
104. Galindo I, Cuesta-Geijo MA, Hlavoa K, Munoz-Moreno R, Barrado-Gil L, Dominguez J, et al. African Swine Fever Virus Infects Macrophages, the Natural Host Cells, via Clathrin- and Cholesterol-Dependent Endocytosis. *Viruses* (2015) 7(6):2004–55. doi: 10.3390/viruses2015.01.022

105. Li C, Deng YQ, Wang S, Ma F, Aliyari R, Huang XY, et al. 25-Hydroxysterol Protects Hosts Against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model. *Immunity* (2017) 46(3):446–56. doi: 10.1016/j.immuni.2017.02.012

106. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, Cocquerel L, Voisset C, Dubuisson J. Hepatitis C Virus Entry: Potential Receptors and Their Cellular Functions. *J Gen Virol* (2006) 87(5):1075–84. doi: 10.1099/vir.0.81646-0

107. Gower TL, Graham BS. Antiviral Activity of Lovastatin Against Respiratory Syncytial Virus *In Vivo* and *In Vitro*. *Antimicrob Agents Chemother* (2001) 45(4):1231–7. doi: 10.1128/AAC.45.4.1231-1237.2001

108. Ravi LI, Li L, Wong PS, Sutejo R, Tan BH, Sugrue RJ. Lovastatin Treatment Inhibit Coxsackievirus-B4 E2 In Vitro and (2013) 98(2):332–43. doi: 10.1111/j.1365-2054.2013.03853.x

109. Griffiths CD, Bilawchuk LM, McDonough JE, Jamieson KC, Elawar F, Cen Y, Anderson CS, Chirkova T, Slaunwhite CG, Qiu X, Walsh EE, Anderson LJ. CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Inflammatory Cytokine Response in Respiratory Syncytial Virus In Vivo and (2011) 32(2):63–70. doi: 10.1016/j.antiviral.2010.03.015

110. Shrivastava-Ranjan P, Flint M, Bergeron E, McElroy AK, Chatterjee P, Lifschitz L. Inhibition of NuclearL and Dysregulation of Cilia-Related Genes. *J Immunol Res* (2015) 2015:1397647. doi: 10.1155/2015/1397647

111. Yuan K, Huang C, Fox J, Gaid M, Weaver A, Li G, et al. Elevated Inflammatory Response in Caveolin-1-Deficient Mice With Pseudomonas Aeruginosa Infection Is Mediated by STAT3 Protein and Nuclear Factor kappab (NF-Kappab). *J Biol Chem* (2011) 286(24):21814–25. doi: 10.1074/jbc.M111.237628

112. Bartusch C, Prange R. ESCRT Requirements for Murine Leukemia Virus In Vivo. *J Virol* (2011) 95(3):e00660-18. doi: 10.1128/jvi.00660-18

113. Brundton B, Rogers K, Phillips EK, Brouillette RB, Boul S, Butler NS, et al. TIM-1 Serves as a Receptor for Ebola Virus *In Vivo*, Enhancing Viremia and Pathogenesis. *Plots Negl Trop Dis* (2019) 13(6):e0006983. doi: 10.1371/journal.pntd.0006983

114. WuDunn D, Spear PG. Initial Interaction of Herpes Simplex Virus With Cells Is Binding to Heparan Sulfate. *J Virol* (1989) 63(1):52–8. doi: 10.1128/JVI.63.1.52-58.1989

115. Meng B, Ip NC, Prestwood LA, Albin R, Gutierrez K, Alibek K, Lever AM. Evidence That the Endosomal Sorting Complex Required for Effi cient Human Immunodeficiency Virus-1 (HIV-1) Production. *Retrovirology* (2015) 12:72. doi: 10.1186/s12977-015-0197-x

116. Bartusch C, Prange R. ESCRT Requirements for Murine Leukemia Virus Release. *Viruses* (2016) 8(4):103. doi: 10.3390/v8040103

117. Christ L, Raiborg C, Wenzel EM, Campstean C, Stenmark H. Cellular Functions and Molecular Mechanisms of the ESCRT Membrane-Scission Machinery. *Trends Biochem Sci* (2017) 42(1):42–56. doi: 10.1016/j.tibs.2016.08.016

118. Dubois I, Ronquix KK, Ek B, Ronquix G, Larsson A. Proteomic Profiling of Detergent Resistant Membranes (Lipid Rafts) of Prostasomes. *Mol Cell Proteomics* (2015) 14(11):3015–22. doi: 10.1074/mcp.M114.047530

119. Martinez-Gutierrez M, Castellanos JE, Gallego-Gomez JC. Statins Reduce Dengue Virus Production via Decreased Virion Assembly. *Intervirology* (2011) 54(2):202–16. doi: 10.1159/000321892

120. Sviridov D, Miller YL, Ballout RA, Remaley AT, Bukinsky M. Targeting Lipid Rafts-A Potential Therapy for COVID-19. *Front Immunol* (2020) 11:574508. doi: 10.3389/fimmu.2020.574508

121. Tsuchiya H, Mizogami M. Interaction of drugs with lipid raft membrane domains as a possible target. *Drug Target Insights* (2020) 14:34–47. doi: 10.33393/dti.2020.2183

122. Lahmam S, Parmryd I. Cholesterol Depletion Using Methyl-Beta-Cyclodextrin. *Methods Mol Biol* (2013) 1232:91–102. doi: 10.1007/978-1-4939-1752-5_8

123. Braga SS, Barbosa JS, Santos NE, El-Saleh F, Pazz FA. Cyclodextrins in Antiviral Therapeutics and Vaccines. *Pharmaceutics* (2021) 13(3):409. doi: 10.3390/pharmaceutics13030409
114. Parihar SP, Guler R, Brombacher F. Statins: A Viable Candidate for Host-Directed Therapy Against Infectious Diseases. Nat Rev Immunol (2019) 19 (7):104–17. doi: 10.1038/s41577-018-0094-3

115. Gorabi AM, Kiaie N, Bianconi V, Jamialahmadi T, Al-Rasadi K, Johnston TP, et al. Antiviral Effects of Statins. PLoS Pathog (2020) 16 (2):e1008468

116. Otreba M, Kosmider L, Rzepecka-Stojko A. Antiviral Activity of Lipid Rafts in Pathogen-Host Interaction. Front Immunol (2020) 11 (24):3757–66. doi: 10.3389/fimmu.2020.010154

117. Ben J, Jiang B, Wang D, Liu Q, Zhang Y, Qi Y, et al. Major Vault Protein (MVP) Negatively Regulates Osteoclastogenesis via Calcineurin-NFATC1 Pathway Inhibition. Theranostics (2021) 11(15):2747–61. doi: 10.7150/thno.85846

118. Kim E, Lee S, Mian MF, Yun SU, Song M, Yi KS, et al. Crosstalk Between Src and Major Vault Protein in Epidermal Growth Factor-Dependent Cell Signalling. FEBS J (2006) 273(4):793–804. doi: 10.1111/j.1742-4658.2006.05112.x

119. Motsch N, Pfühl T, Mrazek J, Barth S, Grassner FA. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 (LMP1) Induces the Expression of the Cellular microRNA mir-146a. RNA Biol (2007) 4(3):131–7. doi: 10.4161/rna.4.3.45206

120. Mrazek J, Kreutmayr SB, Grassner FA, Polacek N, Hutterhofer A, Subtractive Hybridization Identifies Novel Differentially Expressed ncRNA Species in EBV-Infected Human B Cells. Nucleic Acids Res (2007) 35(10):e73. doi: 10.1093/nar/gkm244

121. Kowalski MP, Duboux-Bourandy A, Bajmoczi M, Golan DE, Zaidi T, Coutinho-Sledge YS, et al. Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells. Science (2007) 317(5834):130–2. doi: 10.1126/science.1142311

122. Rayo J, Gregor R, Jacob NT, Dandela R, Dubinsky L, Yashkin A, et al. Immunoediting Role for Major Vault Protein in Apoptotic Signaling Induced by Bacterial N-Acyl Homoserine Lactones. Proc Natl Acad Sci USA (2021) 118(12):e2012529118. doi: 10.1073/pnas.2012529118

123. Ben J, Zhang Y, Zhou H, Zhang H, Zhu X, Li X, et al. Major Vault Protein Regulates Class A Scavenger Receptor-Mediated Tumor Necrosis Factor-Alpha Synthesis and Apoptosis in Macrophages. J Biol Chem (2013) 288(27):20076–84. doi: 10.1074/jbc.M112.449538

124. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. The Major Vault Complex. Cell Mol Life Sci (2003) 60(9):1828–37. doi: 10.1007/s00018-003-3030-y

125. van Zon A, Mossink MH, Schepers RI, Sonneveld P, Wiemer EA. The Vault Complex. Cell Mol Life Sci (2003) 60(9):1828–37. doi: 10.1007/s00018-003-3030-y

126. Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. Cellular Functions of Vaults and Their Involvement in Multidrug Resistance. Curr Drug Targets (2006) 7(8):923–4. doi: 10.2174/138945006778019345

127. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Schepers RI, Lung Resistance-Related Protein/Major Vault Protein and Vaults in Multidrug-Resistant Cancer. Curr Opin Oncol (2000) 12(6):550–6. doi: 10.1097/00018840-200011000-00007

128. van Zon A, Mossink MH, Schepers RI, Sonneveld P, Wiemer EA. Vaults: A Ribonucleoprotein Particle Involved in Drug Resistance? Oncogene (2003) 22(47):7458–67. doi: 10.1038/sj.onc.1206947

129. Wojtowicz K, Januchowski R, Nowicki M, Zabel M. vPARP Adjusts Ribonucleoprotein Particle Involved in Drug Resistance? Oncogene (2003) 22(47):7458–67. doi: 10.1038/sj.onc.1206947

130. Steiner E, Holzmann K, Kirker C, Elbling L, Micksche M, Sutterlaty H, et al. The Major Vault Protein Is Responsive to and Interferes With Interferon-Gamma-Mediated STAT1 Signals. J Cell Sci (2006) 119(Pt 3):459–69. doi: 10.1242/jcs.02773

131. Kolli S, Zito CJ, Mossink MH, Wiemer EA, Rennett AM. The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling. J Biol Chem (2004) 279(28):29374–85. doi: 10.1074/jbc.M313955200

132. Ben J, Jiang B, Wang D, Liu Q, Zhang Y, Qi Y, et al. Major Vault Protein Suppresses Obesity and Atherosclerosis Inhibiting IKK-NF-kappaB Signaling Mediated Inflammation. Nat Commun (2010) 1(1):1801. doi: 10.1038/ncomms1801

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kulkarni, Wiemer and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.